Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Treatment of chronic anal fissure in Crohn's disease patients with freshly collected autologous adipose tissue: a pilot study

Sulaiman A., Dige A., Nordholm AH., Lundby L.

Prospective Study with a reported sample of 4 on Chronic Wound, Autoimmune Research, published in Tech Coloproctol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Tech Coloproctol (2025)
Reported sample size
4
Source database
Europe PMC
PMID
41275461
PMCID
PMC12669252
DOI
10.1007/s10151-025-03230-3

Abstract (original English)

Background Chronic anal fissures in patients with Crohn's disease (CD) remain a significant therapeutic challenge, particularly when linked to active perianal disease. Conventional treatments often fail, highlighting the need for alternative approaches. This study explores the efficacy and safety of freshly collected autologous adipose tissue injection (AATI) for treating chronic fissures in patients with CD. Methods Nine patients with CD with anal fissures were included. The primary outcome was complete healing (CH) at 3 months after last AATI, defined as full fissure re-epithelialization and complete pain relief. Secondary outcomes included changes in defecation pain (visual analog scale [VAS]), anal discomfort (VAS), Perianal Disease Activity Index (PDAI), and St. Mark's Incontinence Score (SMIS). Results Five patients (56%) achieved CH after one (n = 4) or two (n = 1) AATI. Partial healing was observed in four patients (44%). Defecation pain improved from a VAS score of 7.5 (IQR 5.0-8.5) to 2.75 (0.0-4.5; p = 0.009), anal discomfort from VAS score of median 5.0 (2.5-6.5) to 1.0 (0.0-2.5; p = 0.014), PDAI from 5.0 (3.0-6.0) to 1.0 (1.0-2.0; p = 0.022), and SMIS from 7.0 (4.0-9.0) to 4.0 (0.0-4.0; p = 0.041). No treatment-related complications occurred. Conclusion AATI may be a promising new treatment of chronic anal fissures in patients with CD. Effects of AATI should be exp

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueHumansCrohn DiseaseFissure in AnoChronic DiseasePain MeasurementTreatment OutcomeTransplantation, AutologousPilot ProjectsWound Healing

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research